This is the authors' abstract. We don't add key points for this paper.
Radioiodine (RAI) therapy has been used to treat thyroid diseases for around 80 years, and yet it is only relatively recently that we are beginning to manipulate its use, as we understand more of the cellular complexities which govern its success. From the benign nature of hyperthyroidism to malignant thyroid carcinomas and their metastases, RAI has profoundly changed the management of thyroid disorders. However, the complex journey which has elicited this simple therapy is worth exploring.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Souza et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: